A U.S. study of over 500 youth aged 14–24 found high awareness but widespread hesitation about using semaglutide for weight ...

Compared with other antidiabetic medications, semaglutide was linked to a significantly lower risk of opioid overdose in ...

Despite the current downward trend, long-term investors may stay invested in NVO stock due to strong demand for its GLP-1 ...

A U.S. judge on Thursday rejected a bid by compounding pharmacies to keep making copies of Novo Nordisk's popular diabetes ...

Viking's Q1 earnings show no revenue, increased R&D spending, and a substantial cash reserve, positioning it well for future ...

A new expert review endorses GLP-1 RAs and other medications for sustainable weight loss in children with obesity and MASLD.

The MOU marks a significant step in strengthening the Kingdom’s healthcare sector and pharmaceutical manufacturing ...

SIGNIFICANT EVENTS DURING 1 JANUARY - 31 MARCH 2025Iconovo and Lonza have entered a collaboration to develop spray-dried formulations of an intranasal biologic drug for Iconovo's proprietary intranasa ...

April 24 - A U.S. judge on Thursday rejected a bid by compounding pharmacies to keep making copies of Novo Nordisk's popular diabetes and weight-loss drugs Ozempic and Wegovy while a legal challenge ...

The Irish Examiner’s enduring health and wellbeing section has never shied away from intimate or taboo topics, givingprivate ...